PPC
IMCR icon

Park Place Capital’s Immunocore IMCR Stock Holding History

Park Place Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26
Closed -$784 – 1108
2026
Q1 		$784 Hold
26
– – ﹤0.01% 822
2025
Q4 		$902 Hold
26
– – ﹤0.01% 767
2025
Q3 		$945 Hold
26
– – ﹤0.01% 760
2025
Q2 		$854 Hold
26
– – ﹤0.01% 782
2025
Q1 		$771 Buy
+26
New +$780 ﹤0.01% 794
2024
Q4 		– Sell
-29
Closed -$903 – 844
2024
Q3 		$903 Hold
29
– – ﹤0.01% 829
2024
Q2 		$983 Hold
29
– – ﹤0.01% 833
2024
Q1 		$1.89K Buy
+29
New +$1.99K ﹤0.01% 831
2023
Q4 		– Sell
-17
Closed -$882 – 944
2023
Q3 		$882 Hold
17
– – ﹤0.01% 982
2023
Q2 		$1.02K Buy
+17
New +$970 ﹤0.01% 983

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Park Place Capital's IMCR Position: Q2 2026 in Review

Park Place Capital sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 26 shares — an estimated $784 sold.

Park Place Capital first reported a position in IMCR in Q2 2023 and held it in 10 quarters. The position peaked at $1.89K in Q1 2024. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Park Place Capital reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Park Place Capital sold 26 Immunocore shares in Q2 2026, an estimated $784.
  • Park Place Capital first reported a position in Immunocore in Q2 2023 and held it in 10 quarters.
  • Park Place Capital's Immunocore position peaked at $1.89K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.